| Literature DB >> 29985913 |
Chatanun Eamudomkarn1,2, Paiboon Sithithaworn1,2, Christine Kamamia3, Anna Yakovleva3, Jiraporn Sithithaworn4,5, Sasithorn Kaewkes1, Anchalee Techasen2,4, Watcharin Loilome2,6, Puangrat Yongvanit2,6, Chompunoot Wangboon7, Prasert Saichua8, Makoto Itoh9, Jeffrey M Bethony3.
Abstract
The diagnosis of strongyloidiasis by coprological methods has a low sensitivity, underestimating the prevalence of Strongyloides stercoralis in endemic areas. Serodiagnostic tests for strongyloidiasis have shown robust diagnostic properties. However, these methods require a blood draw, an invasive and labor-intensive sample collection method, especially in the resource-limited settings where S. stercoralis is endemic. Our study examines a urine-based assay for strongyloidiasis and compares its diagnostic accuracy with coprological and serological methods. Receiver operating characteristic (ROC) curve analyses determined the diagnostic sensitivity (D-Sn) and specificity (D-Sp) of the urine ELISA, as well as estimates its positive predictive value and diagnostic risk. The likelihood ratios of obtaining a positive test result (LR+) or a negative test result (LR-) were calculated for each diagnostic positivity threshold. The urine ELISA assay correlated significantly with the serological ELISA assay for strongyloidiasis, with a D-Sn of 92.7% and a D-Sp of 40.7%, when compared to coprological methods. Moreover, the urine ELISA IgG test had a detection rate of 69%, which far exceeds the coprological method (28%). The likelihood of a positive diagnosis of strongyloidiasis by the urine ELISA IgG test increased significantly with increasing units of IgG detected in urine. The urine ELISA IgG assay for strongyloidiasis assay has a diagnostic accuracy comparable to serological assay, both of which are more sensitive than coprological methods. Since the collection of urine is easy and non-invasive, the urine ELISA IgG assay for strongyloidiasis could be used to screen populations at risk for strongyloidiasis in S. stercoralis endemic areas.Entities:
Mesh:
Substances:
Year: 2018 PMID: 29985913 PMCID: PMC6037348 DOI: 10.1371/journal.pone.0192598
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Flow chart of participants in the study.
Data shown for age are mean ± SD, where n is the sample size.
Demographic data and detail parasitic infections of the field collected sample subjects for assessment of diagnosis performance study.
Data shown were number of subjects, mean and S.D.
| Group | Other parasite infection | Negative | Total | |
|---|---|---|---|---|
| Total | 41 | 22 | 86 | 149 |
| Male | 18 | 8 | 28 | 54 |
| Female | 23 | 14 | 58 | 95 |
| Age (years) | 57.2 ± 12.1 | 59.6 ±13.1 | 54.9±10.9 | 56.2 ± 11.6 |
| Age by strata | ||||
| 20–40 | 2 | 1 | 3 | 6 |
| 41–60 | 20 | 10 | 59 | 89 |
| 60+ | 19 | 11 | 24 | 54 |
| Intensity of Infection | ||||
| LPG | 18.2 ± 9.2 | 0 | 0 | |
*LPG refers to larvae per gram of feces
Fig 2Venn diagrams comparing the distribution of positive and negative results by each diagnostic method.
Fig 3Tests for cross reactivity with other parasites and disease for strongyloidiasis.
Tests for cross reactivity of the urine ELISA (A) and serum ELISA (B) for strongyloidiasis. (SS, S. stercoralis; OV; O. viverrini; T, Taenia sp.; Tt, T. trichuira; Echi, Echinostomes; MIF, minute intestinal flukes; Ac, A. cantonensis; Pw, P. westernmani; Pm, P. miyazakii; F, Fasciola spp.; Cs, C. sinensis; CCA, cholangiocarcinoma, Cholec, cholecystitis; and Adeno, adenocarcinoma).
Diagnostic performance of antibody detection by the urine assay and serum assay compared with the primary and composite reference standard.
| A. Primary reference standard (41 infected, 108 uninfected) | |||||||
| Diagnostic | Sensitivity | Specificity (%) | Predictive value (%) | ||||
| Positive | Negative | ||||||
| Urine | 0.731 | 92.7 | 40.7 | 37.2 | 93.6 | 1.6 | 0.2 |
| Serum | 0.867 | 95.1 | 45.3 | 39.8 | 96.1 | 1.7 | 0.1 |
| B. Composite reference standard | |||||||
| Diagnostic | Sensitivity | Specificity (%) | Predictive value (%) | ||||
| Positive | Negative | ||||||
| Urine | 0.782 | 80.0% | 55.1% | 78.4 | 57.5 | 1.8 | 0.4 |
| Serum | 0.763 | 77.1% | 61.4% | 82.7 | 52.9 | 2.0 | 0.4 |
*AUC refers to the area under the Receiver operating characteristic (ROC) curve. Positive Predictive Value (PPV), Negative Predictive Value (NPV) and Likelihood Ratios (LR) were estimated using 50% prevalence rate of strongyloidiasis.
LR+ refers to the likelihood of observing a positive test result in patients with strongyloidiasis, and LR- refers to the likelihood, after subtracting from 1, of observing a negative test result with individuals without strongyloidiasis infection
Fig 4The comparison of the ROC curves.
The ROC curve illustrates the comparison between the diagnostic performance of antibody detection using a urine assay and a serum assay. The model used to construct the ROC curve was modeled to include negative controls (strongyloidiasis negative and other infections) and individuals who were infected with strongyloidiasis. A; Primary reference standard for serum and urine ELISA, B; Composite reference standard for serum ELISA, C; Composite reference standard for urine ELISA.
Odd ratios and 95% confidence intervals for predicting the presence of Strongyloides stercoralis infection by the detection of IgG against a crude S. ratti antibody in urinary or serum.
| Predicting strongyloidiasis using urine ELISA assay | ||||
| Unit | Odds Ratio | 95% CI | Adjusted | 95% CI |
| 1.0 | 0.998 | 0.997–0.999 | 1.002 | 1.000–1.001 |
| 100.0 | 1.057 | 1.023–1.109 | 1.038 | 1.004–1.085 |
| 500.0 | 1.320 | 1.120–1.680 | 1.203 | 1.020–1.503 |
| 1000.0 | 1.742 | 1.254–2.821 | 1.446 | 1.041–2.260 |
| Predicting strongyloidiasis using serum ELISA assay | ||||
| Unit | Odds Ratio | 95% CI | Adjusted | 95% CI |
| 1.0 | 1.002 | 1.001–1.003 | 0.998 | 0.997–0.999 |
| 100.0 | 1.202 | 1.126–1.301 | 1.206 | 1.113–1.333 |
| 500.0 | 2.513 | 1.428–2.200 | 2.552 | 1.706–4.213 |
| 1000.0 | 6.317 | 1.812–2.723 | 6.513 | 2.909–17.748 |
a CI refers to confidence interval.
b Adjusted for eosinophil count.
Fig 5Correlation between urine IgG and serum IgG antibodies.
Log-transformed variables. Correlation coefficient determined by Pearson product-moment correlation test.
Test for agreement between two diagnostic methods.
| Kappa value | ||||
|---|---|---|---|---|
| Diagnostic test | Primary | Composite | Serum ELISA | Urine ELISA |
| Serum ELISA | 0.28 | 0.60 | / | |
| Urine ELISA | 0.23 | 0.65 | 0.33 | / |
The number of cases with eosinophilia as classified by results of each diagnostic methods. Absolute eosinophil count >500 cell/μl = eosinophilia.
| Diagnostic tests | Eosinophilia | |
|---|---|---|
| Positive diagnostic result | Negative diagnostic result | |
| Fecal examination | 21/38 (55.3%) | 21/83 (25.3%) |
| Serum ELISA | 36/81 (44.4%) | 6/40 (15.0%) |
| Urine ELISA | 31/81 (38.3%) | 11/40 (27.5%) |